相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Survival improvement for patients with metastatic colorectal cancer over twenty years
Fadl A. A. Zeineddine et al.
NPJ PRECISION ONCOLOGY (2023)
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
Giovanni Fuca et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy
Keigo Chida et al.
CLINICAL CANCER RESEARCH (2022)
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
Aristeidis E. Boukouris et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials
Marco Dubois et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Luis A. Diaz et al.
LANCET ONCOLOGY (2022)
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Eleonora Lai et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Uncovering key targets of success for immunotherapy in pancreatic cancer
Andrea Pretta et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Immune Checkpoint Inhibitors in the Treatment of HCC
Clelia Donisi et al.
FRONTIERS IN ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance
Agata A. Bielska et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J. Casak et al.
CLINICAL CANCER RESEARCH (2021)
CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14
Haitao Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre et al.
LANCET ONCOLOGY (2021)
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Pina Ziranu et al.
TARGETED ONCOLOGY (2021)
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year followup from CheckMate 142
T. Andre et al.
ANNALS OF ONCOLOGY (2021)
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
A. Trullas et al.
ESMO OPEN (2021)
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Yaohui Gao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns
Hanguang Hu et al.
CANCER MEDICINE (2021)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?
Marco Puzzoni et al.
FUTURE ONCOLOGY (2020)
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study
David Tougeron et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
Kristine Aasebo et al.
FRONTIERS IN ONCOLOGY (2020)
Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions
Bohuslava Vankova et al.
GENES CHROMOSOMES & CANCER (2020)
Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Eleonora Lai et al.
CANCERS (2020)
Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis
Junichi Mazaki et al.
BMC CANCER (2020)
Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis
Holger Rumpold et al.
BMC CANCER (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
A. B. Schrock et al.
ANNALS OF ONCOLOGY (2019)
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong et al.
CANCER DISCOVERY (2019)
CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression
Joseph A. Westrich et al.
ONCOGENE (2019)
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco et al.
CANCER RESEARCH (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway
Janina Graule et al.
CLINICAL EPIGENETICS (2018)
Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status
Tsuyoshi Hamada et al.
CANCER IMMUNOLOGY RESEARCH (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A. Fabrizio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Immunotherapy for colorectal cancer: where are we heading?
Debora Basile et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer
Mao Lin et al.
IMMUNOLOGIC RESEARCH (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
Laura Demurtas et al.
BRITISH JOURNAL OF CANCER (2017)
The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton
Nadine Platet et al.
CANCER LETTERS (2017)
Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
Toshiko Kamata et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
CXCL14 as an emerging immune and inflammatory modulator
Jing Lu et al.
JOURNAL OF INFLAMMATION-LONDON (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Piero Dalerba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Enric Domingo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients
Jeong Mo Bae et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection
Jun Zeng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
M. Scartozzi et al.
BRITISH JOURNAL OF CANCER (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Innate or Adaptive Immunity? The Example of Natural Killer Cells
Eric Vivier et al.
SCIENCE (2011)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas
V Kaimaktchiev et al.
MODERN PATHOLOGY (2004)
Colorectal carcinogenesis: MSI-H versus MSI-L
TM Pawlik et al.
DISEASE MARKERS (2004)
分享论文
